Loading…
Reported covered position: Sr. Manager, Federal Government Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Preserving Access to Orphan Drugs Act of 2013
Client: CSL BEHRING LLC · Firm: CSL BEHRING LLC
Preserving Access to Orphan Drugs Act (HR 2315/S1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit
Preserving Access to Orphan Drugs Act of 2013
Client: CSL BEHRING LLC · Firm: CSL BEHRING LLC
Preserving Access to Orphan Drugs Act (HR 2315/S.1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CSL BEHRING LLC via CSL BEHRING LLC
2016 · third_quarter · Q3
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
Orphan drug exclusion from the branded annual pharmaceutical fee Medicare product access Appropriations report language specific to NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Source: Senate LDA
Preserving Access to Orphan Drugs Act of 2013
Client: CSL BEHRING LLC · Firm: CSL BEHRING LLC
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
Preserving Access to Orphan Drugs Act of 2013
Client: CSL BEHRING LLC · Firm: CSL BEHRING LLC
Preserving Access to Orphan Drugs Act (HR 2315/S.1128) Orphan Drug Tax Credit - highlighting its importance in orphan product development for treatment of rare diseases
Preserving Access to Orphan Drugs Act of 2013
Client: CSL BEHRING LLC · Firm: CSL BEHRING LLC
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
Preserving Access to Orphan Drugs Act (HR 2315/S1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit
Preserving Access to Orphan Drugs Act (HR 2315/S.1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
Preserving Access to Orphan Drugs Act (HR 2315/S.1128) Orphan Drug Tax Credit - highlighting its importance in orphan product development for treatment of rare diseases
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
2016 · second_quarter · Q2
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
CSL BEHRING LLC via CSL BEHRING LLC
2016 · first_quarter · Q1
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2015 · fourth_quarter · Q4
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2015 · third_quarter · Q3
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2015 · second_quarter · Q2
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH
Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2015 · first_quarter · Q1
Orphan drug exclusion from the annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit as part of any tax reform package
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2014 · fourth_quarter · 4A
Preserving Access to Orphan Drugs Act (HR 2315/S1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
CSL BEHRING LLC via CSL BEHRING LLC
2014 · fourth_quarter · Q4
Preserving Access to Orphan Drugs Act (HR 2315/S.1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
CSL BEHRING LLC via CSL BEHRING LLC
2014 · third_quarter · 3A
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2014 · third_quarter · Q3
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2014 · second_quarter · Q2
Preserving Access to Orphan Drugs Act (HR 2315/S.1128) Orphan Drug Tax Credit - highlighting its importance in orphan product development for treatment of rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2014 · first_quarter · Q1
Orphan Product Tax issues - Advocating for the Preserving Access to Orphan Drugs Act. Advocating for preservation of the orphan drug tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2013 · fourth_quarter · Q4
Orphan Drug Product issues - annual branded pharmaceutical fee; preservation of the orphan drug tax credit; access to rare disease therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2013 · third_quarter · Q3
Affordable Care Act Issues - annual branded pharmaceutical fee 340B Public Health Service Pricing Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE